AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-04. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
1993/3026) Value Added Tax (General) (Amendment) (No.7) Regulations 1993 (S.I. 1993/3027) Value Added Tax (Cash Accounting) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/3028) Trade Marks and Service Marks (Fees) (Amendment) Rules 1993 (S.I. 1993/3029) Local Government Superannuation (Educational Institutions) Regulations 1993 (S.I. 1993/3030) Transfrontier Shipment of Radioactive Waste Regulations 1993 (S.I. 1993/3031) Gipsy Encampments (Metropolitan District of Salford) Order 1993 (S.I. 1993/3032) A564 Trunk Road Stoke—Derby Route (Doveridge Bypass and Slip Roads) Order 1993 (S.I. 1993/3033) A564 Trunk Road Stoke—Derby Route (Doveridge Bypass) (Detrunking) Order 1993 (S.I. 1993/3034) Local Government Act 1988 (Defined Activities) (Exemption) (Cambridge City Council) Order 1993 (S.I. 1993/3035) Sheep Annual Premium and Suckler Cow Premium Quotas (Amendment) Regulations 1993 (S.I. 1993/3036) Census of Production Order 1993 (S.I. 1993/3037) Licensing of Air Carriers (Second Amendment and Other Provisions) Regulations 1993 (S.I. 1993/3039) Access for Community Air Carriers to Intra-Community Air Routes (Amendment and Other Provisions) Regulations 1993 (S.I. 1993/3040) Air Fares (Second Amendment) Regulations 1993 (S.I. 1993/3041) Airports Slot Allocation (Amendment) Regulations 1993 (S.I. 1993/3042) Local Government Superannuation (Membership) Regulations 1993 (S.I. 1993/3043) Local Government Superannuation (Scotland) Amendment (No.3) Regulations 1993 (S.I. 1993/3044) Land Registration (Leasehold Reform) Rules 1993 (S.I.
=== Pregnancy and breastfeeding === Currently, melarsoprol is not recommended for use in pregnant women. The World Health Organization suggests that treatment be deferred until immediately after delivery since the effects of the medication on the developing fetus have not yet been established. Lactation guidelines associated with melarsoprol have not yet been established.
Pauling had been practically apolitical until World War II. At the beginning of the Manhattan Project, Robert Oppenheimer invited him to be in charge of the Chemistry division of the project. He declined, not wanting to uproot his family.
==== Social services and Social Security ==== Following Republican efforts to pass the Medicare Act of 2003, Bush signed the bill, which included major changes to the Medicare program by providing beneficiaries with some assistance in paying for prescription drugs, while relying on private insurance for the delivery of benefits. The retired persons lobby group AARP worked with the Bush Administration on the program and gave its endorsement. Bush said the law, estimated to cost $400 billion over the first ten years, would give the elderly "better choices and more control over their health care". Bush began his second term by outlining a major initiative to reform Social Security, which was facing record deficit projections beginning in 2005. Bush made it the centerpiece of his domestic agenda despite opposition from some in the U.S. Congress. In his 2005 State of the Union Address, Bush discussed the potential impending bankruptcy of the program and outlined his new program, which included partial privatization of the system, personal Social Security accounts, and options to permit Americans to divert a portion of their Social Security tax (FICA) into secured investments. Democrats opposed the proposal to partially privatize the system. Bush embarked on a 60-day national tour, campaigning for his initiative in media events known as "Conversations on Social Security" in an attempt to gain public support.
=== Corticosteroids === Glucocorticoids, such as prednisone or methylprednisolone, are sometimes used in the treatment of ankylosing spondylitis to manage acute flares and provide short-term relief from inflammation and symptoms. They are powerful anti-inflammatory medications that can help reduce pain, swelling, and stiffness associated with AS. However, glucocorticoids are generally not recommended for long-term use. They are more commonly used as localized injections when someone with AS has a temporary pain flare in a particular joint or area.
Sources: en.wikipedia.org
In 2012, 37.1% of infants under six months of age were breastfeeding exclusively, which rose to 48% in 2022. The Sustainable Development Goals target is to achieve 70% by 2030. In the United States, the rate of women beginning to breastfeed was 76% in 2009, increasing to 83% in 2015, with 58% still breastfeeding at 6 months, although only 25% were still breastfeeding exclusively. African-American women have persistently low rates of breastfeeding compared to White and Hispanic American women. In 2014, 58.1% of African-American women breastfeed in the early postpartum period, compared to 77.7% of White women and 80.6% of Hispanic women. In 2019, 84.1% of U.S women giving birth initiated breastfeeding, with 87.4%, 85.5%, 73.6%, 90.3% and 83.1% of Hispanic, White, African-American, Asian and Multiracial mothers initiating, respectively. Rates of initiation among African-American mothers varied widely by state, with lows under 53% and highs over 90%. Breastfeeding rates in different parts of China vary considerably. Rates in the United Kingdom were the lowest in the world in 2015, with only 0.5% of mothers still breastfeeding at a year, while in Germany, 23% are doing so, 56% in Brazil, and 99% in Senegal. In Australia, for children born in 2004, more than 90% were initially breastfed. In Canada, for children born in 2005–06, more than 50% were only breastfed, and more than 15% received both breastmilk and other liquids by the age of 3 months.
== Diagnosis == Diagnosis can be suspected by symptoms and abnormalities in test, such as: atrophy of cerebellum on MRI, elevated levels of alpha-fetoprotein and cholesterol, neuropathic pattern on electromyography (procedure when a needle is inserted into a muscle in order to measure muscle activity caused by neurons). Consequently, diagnosis can be confirmed via genetic testing.
== See also == Iran and weapons of mass destruction Catholic peace traditions Christian pacifism Christianity and violence Just war theory Peace churches Reactions to the 2026 Iran war Regime change efforts in the 2026 Iran war Analysis of the 2026 Iran war Use of religious language and symbolism in the Gaza war
Anatomy figure: 22:01-03 at Human Anatomy Online, SUNY Downstate Medical Center (Posterior) Anatomy figure: 22:03-02 at Human Anatomy Online, SUNY Downstate Medical Center (Lateral) "Anatomy diagram: 34256.000-2". Roche Lexicon - illustrated navigator. Elsevier. Archived from the original on 2014-01-01.
A blood smear is a thin layer of blood smeared on a glass microscope slide and then stained in such a way as to allow the various blood cells to be examined microscopically. This technique can be used to detect sickled cells visually; however, it does not detect sickle cell carriers. A solubility test relies on the fact that HbS is less soluble than normal haemoglobin (HbA); it is highly reliable but does not distinguish between full sickle cell disease and carrier status. Tests which can be used for sickle cell disease as well as for other hemoglobinopathies:
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.